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FOREWORD TO THE SPECIAL ISSUE ON APOPTOSIS
Dear Reader!
The 2012 Special Issue of Experimental Oncology 
is devoted to the 40th anniversary of one of the crucial 
milestones in biology and medicine, recognized today 
as the «birthday» of apoptosis research. The term 
apoptosis was coined by John Kerr, Andrew Wyllie and 
Alastair Currie in the article published in British Journal 
of Cancer in 1972. Besides the important statement 
that apoptosis «is an active, inherently programmed 
phenomenon», the authors speculated that «hyperpla-
sia might sometimes result from decreased apoptosis 
rather than increased mitosis» and also proposed that 
«histological assessment of the «apoptotic index» 
of a tumour several days after the commencement 
of therapy might, in some cases, provide a useful mea-
sure of its response» [1]. Initially met without enthu-
siasm, the concept of apoptosis has been confirmed 
in numerous studies and as of the autumn of 2012, 
this landmark paper had received 11657 (!) citations.
The reviews presented in the issue prove the tre-
mendous progress made in recent years in the study 
of apoptosis and related phenomena applied to cancer 
research. The contributing authors from Canada, Iran, 
Ireland, Italy, Japan, New Zealand, Switzerland, The 
Netherlands, Ukraine and USA (chiefly) are the authori-
tative experts in their fields. Two opening reviews deal 
with historical aspects of cell death research [2, 3]. The 
following four papers are devoted to the analysis of ex-
trinsic, death receptor-dependent apoptotic pathway, 
providing an outlook on caspase-8-mediated cell-
suicide signaling [4–7]. The role of c-FLIP isoforms 
as critical anti-apoptotic/drug resistance factors and 
novel c-FLIP targeted agents for cancer therapy are 
also discussed [7]. Subsequent two papers provide 
in-depth information on the intrinsic (mitochondrial) 
death pathway with particular reference to the role 
of the Bcl-2 family members [8, 9]. The next paper 
describes the inhibitors of apoptosis (IAP) proteins 
and their role in cell death and signaling pathways [10]. 
A great deal of attention has been paid to the devel-
opment and testing of the IAP antagonists. Next, our 
current knowledge of alternative splicing of apoptosis-
associated genes as well as mechanisms of transla-
tion control in apoptosis is summarized [11, 12]. The 
authors of the review [13] dwell on the sphingolipid-
mediated regulation of apoptosis. A detailed discus-
sion of the cell-cycle checkpoint signaling, DNA repair 
system and apoptotic pathways activated in response 
to DNA damage is also presented [14].
The following part of the issue moves from cell 
death signaling to modern approaches used for detec-
tion and quantification of apoptotic cells (see [15–17]). 
The application of in vivo apoptosis imaging by means 
of 99mTc-annexin V scintigraphy to monitor early re-
sponse to therapy is analyzed more thoroughly due 
to the large clinical experience of authors [17]. Recent 
progress in studying cell death and cell proliferation 
during and after radiation treatment is in the focus 
of the following paper [18]. Of special importance are 
the new data on the involvement of tumor microenvi-
ronment in response to irradiation.
Over the decades of the intense research, it is be-
coming clear that several cell death modalities exist 
which are distinct from apoptosis. Some of these cell 
death subroutines including autophagy [19], necrop-
tosis [10], cellular senescence [20] and «cannibalism» 
[21] are mainly discussed in the final part of this issue. 
Since nonapoptotic modes of the cell demise appear 
to be responsible for the elimination of cancer cells, 
both spontaneous and therapy-induced, this informa-
tion will be useful from the viewpoint of the search for 
alternative approaches in cancer therapy.
Finally, I am grateful to all the authors for their ge-
ne rous contributions to this issue. My special thanks 
to Dr. Alex Philchenkov for the original idea and its 
successful realization.
Prof. V.F. Chekhun, Editor-in-Chief
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